Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTAFR | P25105 | 8/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 2/20 | 0.43 |
| ▸ | KDM4B | O94953 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21045159 | 1.00 | PTAFR (0.53) | PTAFRKDM4EEPHX2NPC1RAB9A | |
| SCHEMBL29411410 | 0.89 | KDM4E (0.55) | PTAFRKDM4EEPHX2NPC1RAB9A | |
| SCHEMBL21045178 | 0.89 | KDM4E (0.55) | PTAFRKDM4EEPHX2NPC1RAB9A | |
| SCHEMBL21045131 | 0.87 | PTAFR (0.54) | PTAFRKDM4E | |
| SCHEMBL29411534 | 0.87 | PTAFR (0.54) | PTAFRKDM4E | |
| SCHEMBL29411439 | 0.86 | PTAFR (0.48) | PTAFRKDM4E | |
| SCHEMBL21045275 | 0.86 | PTAFR (0.48) | PTAFRKDM4E | |
| SCHEMBL21045340 | 0.82 | PTAFR (0.59) | PTAFRKDM4EEPHX2NPC1RAB9A | |
| SCHEMBL21045299 | 0.82 | PTAFR (0.62) | PTAFRKDM4EEPHX2NPC1RAB9A | |
| SCHEMBL29411467 | 0.82 | PTAFR (0.59) | PTAFRKDM4EEPHX2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188035-A1 | TUBULIN INHIBITORS | LIN BIOSCIENCE LLC (US) | 2025-06-12 | — | — | US | disclosed |
| US-12247010-B2 | Tubulin inhibitors | LIN BIOSCIENCE INC. (TW) | 2025-03-11 | — | — | US | disclosed |
| US-20220089539-A1 | TUBULIN INHIBITORS | LIN BIOSCIENCE INC. (TW) | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089539-A1 | TUBULIN INHIBITORS | TUBB3, TUBB1, TUBB | PTAFR 2124/4885KDM4E 4032/4885EPHX2 4380/4885 |
| US-12247010-B2 | Tubulin inhibitors | TUBB3, TUBB1, TUBB | PTAFR 2124/4885KDM4E 4032/4885EPHX2 4380/4885 |
| US-20250188035-A1 | TUBULIN INHIBITORS | TUBB3, TUBB1, TUBB | PTAFR 2124/4885KDM4E 4032/4885EPHX2 4380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.